CCR5 and neoplasm: On the other side, tumor cells counteract this axis by releasing PGE2, a molecule that concomitantly inhibits NK cell functionality and DC recruitment via X-C Motif Chemokine Receptor 1 (XCR1) and CCR5 downregulation [57].